RxDoctor Payments Data

Xochitl Landeros

Family · Phoenix, AZNPI 1639649767

Payments from drug & device makers

$1,743in general payments, 2019–2025

Across 54 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • GSK$236
  • Johnson & Johnson$147
  • Lilly USA, LLC$145
  • AbbVie$133
  • Phadia US Inc.$128
  • plus $640 from 14 others

What the payments were for

  • Food & beverage$1,743100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,743 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$14,486
Medicare patients
46
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$84,053
TrulicityDulaglutide30$39,275
FarxigaDapagliflozin Propanediol32$29,891
OzempicSemaglutide18$25,046
JanuviaSitagliptin Phosphate13$19,539
LinzessLinaclotide18$13,775
JanumetSitagliptin Phos/Metformin Hcl11$12,283
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,712
VascepaIcosapent Ethyl11$3,743
Atorvastatin Calcium292$2,663
Gabapentin154$2,512
Omeprazole119$2,279
Lisinopril292$1,820
Ezetimibe35$1,552
Losartan Potassium97$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$56$84,05364 claims
Lilly USA, LLCTrulicity$145$39,27530 claims
Novo NordiskOzempic$314$25,04618 claims
AbbVieLinzess$133$13,77518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →